Literature DB >> 21651457

Candesartan cilexetil: an update.

Alexander Joost1, Heribert Schunkert, Peter Walter Radke.   

Abstract

INTRODUCTION: Candesartan cilexetil is one of the most often-used first-line drugs regarding the management of arterial hypertension. Moreover, this drug has proven its effectiveness in chronic heart failure and exerts beneficial effects in diabetes, stroke, dementia and atrial fibrillation. AREAS COVERED: This review focuses on the use of candesartan cilexetil in Phase II and Phase III trials and their implications for clinical usage in the treatment of arterial hypertension and heart failure. The usage of candesartan cilexetil in patients with stroke, migraine or atrial fibrillation, hypertrophy obstructive or nonobstructive cardiomyopathy and diabetic or non diabetic renal diseases will be discussed. Relevant publications were identified by an extensive Medline search. EXPERT OPINION: Candesartan cilexetil is a highly effective ARB for the treatment of arterial hypertension and heart failure. Also, recent trials have suggested beneficial effects in diabetic patients, patients with nondiabetic renal diseases, stroke, migraine and atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21651457     DOI: 10.1517/14656566.2011.587000

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  3 in total

1.  Quantification of Candesartan in Mouse Plasma by MALDI-TOFMS and in Tissue Sections by MALDI-Imaging Using the Stable-Isotope Dilution Technique.

Authors:  Toyofumi Nakanishi; Shinji Takai; Denan Jin; Takayuki Takubo
Journal:  Mass Spectrom (Tokyo)       Date:  2013-06-01

2.  Repositioning of the Angiotensin II Receptor Antagonist Candesartan as an Anti-Inflammatory Agent With NLRP3 Inflammasome Inhibitory Activity.

Authors:  Wen-Yu Lin; Lan-Hui Li; Ya-Yun Hsiao; Wei-Ting Wong; Hsiao-Wen Chiu; Hsien-Ta Hsu; Yi-Jen Peng; Chen-Lung Ho; Oleg V Chernikov; Shu-Meng Cheng; Shih-Ping Yang; Kuo-Feng Hua
Journal:  Front Immunol       Date:  2022-05-20       Impact factor: 8.786

3.  Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction.

Authors:  Gwo-Jyh Chang; Yung-Hsin Yeh; Wei-Jan Chen; Yu-Shien Ko; Ying-Ju Lai; Yun-Shien Lee
Journal:  J Am Heart Assoc       Date:  2022-07-19       Impact factor: 6.106

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.